News

404

AngioDynamics International Life Symposium November 7 – 9, 2024

AngioDynamics International Life Symposium November 7 – 9, 2024

Immunophotonics co-founders Lu Alleruzzo, CEO and Tomas Hode, PhD, CIO, and President will attend the AngioDynamics International Life Symposium taking place November 7th to 9th in Monte Carlo.  They will engage with industry partners and clinical experts globally, focusing on the latest breakthrough technologies for surgical interventions. Look for Lu and Tomas at this event...

Professor Wei Chen’s publication in Elsevier Cancer Letters an international journal

Congratulations to Professor Wei Chen and his lab University of Oklahoma for their publication titled “Localized ablative immunotherapy enhances antitumor immunity by modulating the transcriptome of tumor-infiltrating Gamma delta T cells” in Elsevier Cancer Letters an international journal providing a forum for original and significant contributions in cancer research. Click here to read the publication

SITC Immuno-Oncology Drug Development Summit September 30 – October 1, 2024

Siu Kit “Samuel” Lam, PhD, Senior Vice President of Science & Research at Immunophotonics, Inc. attended the SITC Immuno-Oncology Drug Development Summit held in Boston from September 30 – October 1, 2024. The program was highly informative, offering valuable insights, essential resources, and best practices for the development of immuno-oncology therapeutics. It also provided opportunities...

Professor Wei Chen’s Publication in Advanced Science News – Advanced Functional Materials

Immunophotonics wants to congratulate Professor Wei Chen and his lab University of Oklahoma, along with contributors Lu Alleruzzo, Samuel S.K. Lam, Tomas Hode, David Anderson, Johnny Wong, Abby Delawder, Joe Raker of Immunophotonics, for their publication titled “N-dihydrogalactochitosan Drives Conventional and Alternative Activations of STING to Synergize Type I IFN and IL-1β Productions of Antitumor...

Immunophotonics, CIRSE, and Next Research Announce Innovative Phase 2/3 Clinical Trial: INJECTABL-3

Immunophotonics is pioneering the field of Interventional Immunology-Oncology™, where a single injection of IP-001 –seamlessly integrated into the clinical workflow– has the potential to transform a routine tumor ablation into a systemic immunotherapy to fight cancer throughout the body. Immunophotonics co-founders Lu Alleruzzo, CEO and Tomas Hode, PhD, CIO, and President are pleased to announce...

CIRSE 2024 September 14 to 18 and ESMO 2024 September 16

Immunophotonics co-founders Lu Alleruzzo (CEO), Tomas Hode, PhD (CIO and President), and David Anderson, PhD (CSO) are excited to be attending CIRSE 2024 Congress taking place in Lisbon, Portugal, September 14th to 18th and ESMO Congress in Barcelona, Spain on September 16th.  They look forward to engaging with fellow professionals, discussing the latest advancement in...

Immunophotonics Winner of the Startup World Cup St Louis Regional Finals

Immunophotonics won the Startup World Cup St. Louis Regional finals. A big thank you to Emily Hemingway and her team at TechSTL for their hard work in organizing this remarkable event. You did an exceptional job! We also want to extend our gratitude to the judges—Vikram Lakhwara, Atul Kamra, Rick Holton Jr., and Julia Campbell—for...

Professor Wei R. Chen Organizes Immunophotonics Session at Gordan Research Conference

Immunophotonics is excited to share that Wei Chen, co-inventor of IP-001, Stephenson Chair, professor and interim director of the Stephenson School of Biomedical Engineering and his team recently organized a session titled “Immunophotonics” for the Gordon Research Conference Optics and Photonics in Medicine and Biology in Lewiston, Maine. During this session, Professor Chen delivered an...

Immunophotonics featured in Pharma Tech Outlook magazine

Immunophotonics is excited to be featured in Pharma Tech Outlook magazine in the Immunotherapy edition.  Immunophotonics innovative approach could transform standard treatments into powerful immunotherapies with IP-001 turning every procedure into an opportunity to mobilize the body’s natural immune system against cancer. “A New Frontier in Treating Cancer: The Great Potential of Interventional Immuno-Oncology™ Link...

Scroll to top